Posted by Michael Wonder on 07 May 2026
Repertoire Immune Medicines announces FDA fast track designation for its investigational immune medicine, RPTR-1-201
7 May 2026 - Repertoire Immune Medicines today announced that the US FDA has granted fast track designation to RPTR-1-201 for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic triple negative breast cancer after progression on, or intolerance to, available standard therapies.
RPTR-1-201 is a novel T cell receptor bi-specific immune medicine that is currently in a Phase 1/2 trial for the treatment of multiple advanced solid tumours.
